Sabrina Sacconi

List of Publications by Year
in descending order

168 papers	6,878 citations	61984 43 h-index	71685 76 g-index
181 all docs	181 docs citations	181 times ranked	6572 citing authors

#	Article	IF	Citations
1	A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy. Science, 2010, 329, 1650-1653.	12.6	638
2	Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nature Genetics, 2012, 44, 1370-1374.	21.4	582
3	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
4	Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology, 2010, 75, 1548-1554.	1.1	215
5	Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: A CoQ10-responsive condition. Neurology, 2005, 65, 606-608.	1.1	184
6	Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Human Mutation, 2009, 30, 1449-1459.	2.5	172
7	EFNS guidelines on the diagnostic approach to pauciâ€•or asymptomatic hyperCKemia. European Journal of Neurology, 2010, 17, 767-773.	3.3	157
8	Mitochondrial DNA depletion. Neurology, 2002, 59, 1197-1202.	1.1	156
9	The FSHD2 Gene SMCHD1 Is a Modifier of Disease Severity in Families Affected by FSHD1. American Journal of Human Genetics, 2013, 93, 744-751.	6.2	154
10	Mitochondrial DNA depletion and dGK gene mutations. Annals of Neurology, 2002, 52, 311-317.	5.3	152
11	Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Human Molecular Genetics, 2015, 24, 659-669.	2.9	130
12	Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study. PLoS ONE, 2016, 11, e0148264.	2.5	113
13	Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trials. European Journal of Paediatric Neurology, 2012, 16, 149-160.	1.6	112
14	A functionally dominant mitochondrial DNA mutation. Human Molecular Genetics, 2008, 17, 1814-1820.	2.9	104
15	The D4Z4 Macrosatellite Repeat Acts as a CTCF and A-Type Lamins-Dependent Insulator in Facio-Scapulo-Humeral Dystrophy. PLoS Genetics, 2009, 5, e1000394.	3.5	99
16	Cytochrome c Oxidase Deficiency Due to a Novel SCO2 Mutation Mimics Werdnig-Hoffmann Disease. Archives of Neurology, 2002, 59, 862-5.	4.5	95
17	Haploinsufficiency ofCOQ4causes coenzyme Q₁₀deficiency. Journal of Medical Genetics, 2012, 49, 187-191.	3.2	95
18	The genetic basis of undiagnosed muscular dystrophies and myopathies. Neurology, 2016, 87, 71-76.	1.1	92

#	Article	IF	Citations
19	Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores. Human Mutation, 2008, 29, 670-678.	2.5	89
20	Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscular Disorders, 2010, 20, 44-48.	0.6	84
21	A novel CRYAB mutation resulting in multisystemic disease. Neuromuscular Disorders, 2012, 22, 66-72.	0.6	84
22	Normal growth and regenerating ability of myoblasts from unaffected muscles of facioscapulohumeral muscular dystrophy patients. Gene Therapy, 2005, 12, 1651-1662.	4.5	72
23	Cytosolic 5â€²-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Annals of the Rheumatic Diseases, 2017, 76, 862-868.	0.9	71
24	Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. Journal of Neurology, 2010, 257, 1730-1733.	3.6	68
25	A Novel Role for the RNAâ€“Binding Protein FXR1P in Myoblasts Cell-Cycle Progression by Modulating p21/Cdkn1a/Cip1/Waf1 mRNA Stability. PLoS Genetics, 2013, 9, e1003367.	3.5	67
26	Copper supplementation restores cytochrome c oxidase activity in cultured cells from patients with SCO2 mutations. Biochemical Journal, 2002, 363, 321-327.	3.7	66
27	Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations. Neuromuscular Disorders, 2015, 25, 533-541.	0.6	65
28	Coats syndrome in facioscapulohumeral dystrophy type 1. Neurology, 2013, 80, 1247-1250.	1.1	63
29	Mutation Screening in Patients With Isolated Cytochrome c Oxidase Deficiency. Pediatric Research, 2003, 53, 224-230.	2.3	62
30	DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles. Human Molecular Genetics, 2014, 23, 171-181.	2.9	61
31	Isolation of a Highly Myogenic CD34-Negative Subset of Human Skeletal Muscle Cells Free of Adipogenic Potential. Stem Cells, 2010, 28, 753-764.	3.2	60
32	Acute Disseminated Encephalomyelitis Associated With Hepatitis C Virus Infection. Archives of Neurology, 2001, 58, 1679.	4.5	57
33	Copper supplementation restores cytochrome c oxidase activity in cultured cells from patients with SCO2 mutations. Biochemical Journal, 2002, 363, 321.	3.7	55
34	Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity. Journal of Medical Genetics, 2012, 49, 41-46.	3.2	55
35	Alteration of expression of muscle specific isoforms of the fragile X related protein 1 (FXR1P) in facioscapulohumeral muscular dystrophy patients. Journal of Medical Genetics, 2008, 45, 679-685.	3.2	54
36	TheCOQ2genotype predicts the severity of coenzyme Q₁₀deficiency. Human Molecular Genetics, 2016, 25, 4256-4265.	2.9	53

#	Article	IF	Citations
37	Dynamic transcriptomic analysis reveals suppression of PGC1Î±/ERRÎ± drives perturbed myogenesis in facioscapulohumeral muscular dystrophy. Human Molecular Genetics, 2019, 28, 1244-1259.	2.9	52
38	A novel gainâ€ofâ€function mutation in ORAI1 causes lateâ€onset tubular aggregate myopathy and congenital miosis. Clinical Genetics, 2017, 91, 780-786.	2.0	50
39	FSHD1 and FSHD2 form a disease continuum. Neurology, 2019, 92, e2273-e2285.	1.1	50
40	Pain assessment in Charcot-Marie-Tooth (CMT) disease. Annals of Physical and Rehabilitation Medicine, 2012, 55, 160-173.	2.3	49
41	Hierarchization of Myogenic and Adipogenic Progenitors Within Human Skeletal Muscle. Stem Cells, 2010, 28, 2182-2194.	3.2	48
42	The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease. Revue Neurologique, 2013, 169, 595-602.	1.5	48
43	Facioscapulohumeral muscular dystrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 607-614.	3.8	47
44	Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novelASLpseudogene. Human Mutation, 2007, 28, 694-702.	2.5	46
45	Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity. Journal of Clinical Investigation, 2017, 127, 1531-1545.	8.2	46
46	Mutation Screening in Patients With Isolated Cytochrome c Oxidase Deficiency. Pediatric Research, 2003, 53, 224-230.	2.3	44
47	Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurology, The, 2021, 20, 1027-1037.	10.2	42
48	Unusual multisystemic involvement and a novel BAG3 mutation revealed by NGS screening in a large cohort of myofibrillar myopathies. Orphanet Journal of Rare Diseases, 2014, 9, 121.	2.7	38
49	A multicenter retrospective study of charcotâ€marieâ€tooth disease type 4B (CMT4B) associated with mutations in myotubularinâ€related proteins (MTMRs). Annals of Neurology, 2019, 86, 55-67.	5.3	35
50	Mini-Exome Coupled to Read-Depth Based Copy Number Variation Analysis in Patients with Inherited Ataxias. Human Mutation, 2016, 37, 1340-1353.	2.5	33
51	Complex Neurologic Syndrome Associated With the G1606A Mutation of Mitochondrial DNA. Archives of Neurology, 2002, 59, 1013.	4.5	32
52	Unusual Clinical Presentations in Four Cases of Leigh Disease, Cytochrome C Oxidase Deficiency, and SURF1 Gene Mutations. Journal of Child Neurology, 2005, 20, 670-674.	1.4	32
53	Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition?. Journal of Neurology, 2009, 256, 1876-1880.	3.6	32
54	Correlation between low <scp>FAT</scp>1 expression and early affected muscle in facioscapulohumeral muscular dystrophy. Annals of Neurology, 2015, 78, 387-400.	5.3	32

#	Article	IF	Citations
55	Low penetrance in facioscapulohumeral muscular dystrophy type 1 with large pathological D4Z4 alleles: a cross-sectional multicenter study. Orphanet Journal of Rare Diseases, 2015, 10, 2.	2.7	32
56	Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. Journal of Neurology, 2019, 266, 680-690.	3.6	31
57	Mitochondrial function in skeletal myofibers is controlled by a TRF2â€SIRT3 axis over lifetime. Aging Cell, 2020, 19, e13097.	6.7	31
58	Mitochondrial myopathy and ophthalmoplegia in a sporadic patient with the G12315A mutation in mitochondrial DNA. Neuromuscular Disorders, 2002, 12, 865-868.	0.6	29
59	NovelSURF1 mutation in a child with subacute encephalopathy and without the radiological features of Leigh Syndrome. American Journal of Medical Genetics Part A, 2004, 128A, 195-198.	2.4	29
60	Neuromuscular Electrical Stimulation Training: A Safe and Effective Treatment for Facioscapulohumeral Muscular Dystrophy Patients. Archives of Physical Medicine and Rehabilitation, 2010, 91, 697-702.	0.9	29
61	Copper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of patients with sco2 mutations. Orphanet Journal of Rare Diseases, 2012, 7, 21.	2.7	29
62	hCOX18 and hCOX19: Two human genes involved in cytochrome c oxidase assembly. Biochemical and Biophysical Research Communications, 2005, 337, 832-839.	2.1	28
63	Long-Term Mechanical Ventilation Equipment for Neuromuscular Patients: Meeting the Expectations of Patients and Prescribers. Respiratory Care, 2014, 59, 97-106.	1.6	28
64	Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. BMC Neurology, 2019, 19, 224.	1.8	28
65	<scp>EFNS</scp> review on the role of muscle biopsy in the investigation of myalgia. European Journal of Neurology, 2013, 20, 997-1005.	3.3	27
66	Quantitative multiplex PCR of short fluorescent fragments for the detection of large intragenic POLG rearrangements in a large French cohort. European Journal of Human Genetics, 2014, 22, 542-550.	2.8	27
67	Lateâ€onset Pompe disease in France: molecular features and epidemiology from a nationwide study. Journal of Inherited Metabolic Disease, 2018, 41, 937-946.	3.6	27
68	Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2. Human Molecular Genetics, 2018, 27, 3488-3497.	2.9	27
69	SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain. Journal of Medical Genetics, 2019, 56, 693-700.	3.2	27
70	Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing. Journal of Medical Genetics, 2019, 56, 828-837.	3.2	27
71	Hepatocerebral Mitochondrial DNA Depletion Syndrome: Clinical and Morphologic Features of a Nuclear Gene Mutation. Journal of Pediatric Gastroenterology and Nutrition, 2004, 38, 216-220.	1.8	25
72	COX16 is required for assembly of cytochrome c oxidase in human cells and is involved in copper delivery to COX2. Biochimica Et Biophysica Acta - Bioenergetics, 2018, 1859, 244-252.	1.0	25

#	Article	IF	Citations
73	FSHD type 2 and Bosma arhinia microphthalmia syndrome. Neurology, 2018, 91, e562-e570.	1.1	24
74	Deciphering the complexity of the 4q and 10q subtelomeres by molecular combing in healthy individuals and patients with facioscapulohumeral dystrophy. Journal of Medical Genetics, 2019, 56, 590-601.	3.2	24
75	Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC). Orphanet Journal of Rare Diseases, 2020, 15, 330.	2.7	23
76	Optimal reconfiguration policy to react to product changes. International Journal of Production Research, 2008, 46, 2651-2673.	7.5	22
77	Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients. Scientific Reports, 2016, 6, 36182.	3.3	22
78	Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2. European Journal of Human Genetics, 2018, 26, 94-106.	2.8	22
79	Diagnostic challenges in facioscapulohumeral muscular dystrophy. Neurology, 2006, 67, 1464-1466.	1.1	21
80	Effect of enzyme replacement therapy with alglucosidase alfa (MyozymeÂ®) in 12 patients with advanced late-onset Pompe disease. Molecular Genetics and Metabolism, 2017, 122, 80-85.	1.1	21
81	Longâ€term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry. Journal of Inherited Metabolic Disease, 2020, 43, 1219-1231.	3.6	21
82	Congenital cardiomyopathy and pulmonary hypertension: Another fatal variant of cytochrome-c oxidase deficiency. Journal of Inherited Metabolic Disease, 2004, 27, 735-739.	3.6	20
83	225th ENMC international workshop:. Neuromuscular Disorders, 2017, 27, 782-790.	0.6	20
84	Construction of a Quality of Life Questionnaire for slowly progressive neuromuscular disease. Quality of Life Research, 2015, 24, 2615-2623.	3.1	19
85	The inward rectifier potassium channel Kir2.1 is required for osteoblastogenesis. Human Molecular Genetics, 2015, 24, 471-479.	2.9	19
86	Dehydroepiandrosterone for myotonic dystrophy type 1. Neurology, 2008, 71, 407-412.	1.1	18
87	Mechanisms underlying Andersen's syndrome pathology in skeletal muscle are revealed in human myotubes. American Journal of Physiology - Cell Physiology, 2009, 297, C876-C885.	4.6	17
88	Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. Acta Neuropathologica Communications, 2019, 7, 167.	5.2	17
89	Comparison of high-frequency and ultrahigh-frequency probes in chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, 2019, 266, 2277-2285.	3.6	16
90	Deep phenotyping of facioscapulohumeral muscular dystrophy type 2 by magnetic resonance imaging. European Journal of Neurology, 2020, 27, 2604-2615.	3.3	16

#	Article	IF	Citations
91	Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease. Neuromuscular Disorders, 2014, 24, 648-650.	0.6	15
92	Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy. Journal of Neuromuscular Diseases, 2022, 9, 83-93.	2.6	15
93	Modeling Andersen's Syndrome in Human Induced Pluripotent Stem Cells. Stem Cells and Development, 2016, 25, 151-159.	2.1	14
94	The quality of life in genetic neuromuscular disease questionnaire: Rasch validation of the French version. Muscle and Nerve, 2017, 56, 1085-1091.	2.2	14
95	Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. Neuromuscular Disorders, 2021, 31, 1124-1135.	0.6	14
96	Motor axonal neuropathy associated with <scp>GNE</scp> mutations. Muscle and Nerve, 2021, 63, 396-401.	2.2	12
97	Meeting report: the 2021 FSHD International Research Congress. Skeletal Muscle, 2022, 12, 1.	4.2	12
98	Monosomy 18p is a risk factor for facioscapulohumeral dystrophy. Journal of Medical Genetics, 2018, 55, 469-478.	3.2	11
99	The French National Registry of patients with Facioscapulohumeral muscular dystrophy. Orphanet Journal of Rare Diseases, 2018, 13, 218.	2.7	11
100	Bent spine syndrome as the initial symptom of lateâ€onset Pompe disease. Muscle and Nerve, 2017, 56, 167-170.	2.2	9
101	Miller Fisher syndrome, Bickerstaff brainstem encephalitis and Guillain-BarrÃ© syndrome overlap with persistent non-demyelinating conduction blocks: a case report. BMC Neurology, 2018, 18, 101.	1.8	9
102	Ultraâ€“highâ€frequency ultrasound imaging of sural nerve: A comparative study with nerve biopsy in progressive neuropathies. Muscle and Nerve, 2021, 63, 46-51.	2.2	9
103	1st FSHD European Trial Network workshop:Working towards trial readiness across Europe. Neuromuscular Disorders, 2021, 31, 907-918.	0.6	9
104	Bilateral scapulothoracic arthrodesis for facioscapulohumeral muscular dystrophy: function, fusion, and respiratory consequences. Journal of Shoulder and Elbow Surgery, 2020, 29, 931-940.	2.6	8
105	The facioscapulohumeral muscular dystrophy Raschâ€built overall disability scale (FSHDâ€RODS). European Journal of Neurology, 2021, 28, 2339-2348.	3.3	8
106	High-resolution breakpoint junction mapping of proximally extended D4Z4 deletions in FSHD1 reveals evidence for a founder effect. Human Molecular Genetics, 2022, 31, 748-760.	2.9	8
107	Mutation analysis of COX18 in 29 patients with isolated cytochrome c oxidase deficiency. Journal of Human Genetics, 2009, 54, 419-421.	2.3	7
108	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscular Disorders, 2016, 26, 462-471.	0.6	7

#	Article	IF	Citations
109	Design, construction, and monitoring of a building with deep basements in Rome. Canadian Geotechnical Journal, 2016, 53, 210-224.	2.8	7
110	Diagnostic challenges in metabolic myopathies. Expert Review of Neurotherapeutics, 2020, 20, 1287-1298.	2.8	7
111	Development and validation of a motor function classification in patients with neuromuscular disease: The NM-Score. Annals of Physical and Rehabilitation Medicine, 2013, 56, 673-686.	2.3	6
112	Long term follow-up of cerebrovascular abnormalities in late onset Pompe disease (LOPD). Journal of Neurology, 2017, 264, 589-590.	3.6	6
113	Short-TERM Neuromuscular Electrical Stimulation Training of the Tibialis Anterior Did Not Improve Strength and Motor Function in Facioscapulohumeral Muscular Dystrophy Patients. American Journal of Physical Medicine and Rehabilitation, 2017, 96, e56-e63.	1.4	6
114	MT-CYB deletion in an encephalomyopathy with hyperintensity of middle cerebellar peduncles. Neurology: Genetics, 2018, 4, e268.	1.9	6
115	Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 1760-1763.	1.2	6
116	Genotypeâ€“phenotype correlation in French patients with myelin protein zero geneâ€related inherited neuropathy. European Journal of Neurology, 2021, 28, 2913-2921.	3.3	6
117	New variant of necklace fibres display peculiar lysosomal structures and mitophagy. Neuromuscular Disorders, 2018, 28, 846-856.	0.6	4
118	Mannose 6â€phosphonate labelling: A key for processing the therapeutic enzyme in Pompe disease. Journal of Cellular and Molecular Medicine, 2019, 23, 6499-6503.	3.6	4
119	Singleâ€fiber studies for assigning pathogenicity of eight mitochondrial DNA variants associated with mitochondrial diseases. Human Mutation, 2020, 41, 1394-1406.	2.5	4
120	CHCHD10 mutations are not a common cause of SMN1â€negative type III/IV spinal motor atrophy. Annals of Neurology, 2015, 78, 831-831.	5.3	3
121	The motor function measure (MFM) in the facio scapulo humeral dystrophy (FSHD) population: Description and responsiveness. Annals of Physical and Rehabilitation Medicine, 2016, 59, e84-e85.	2.3	3
122	Estrogens as a potential disease modifier in FSHD: a retrospective clinical study. Neuromuscular Disorders, 2017, 27, S200.	0.6	3
123	Severe defect in mitochondrial complex I assembly with mitochondrial DNA deletions in ACAD9â€deficient mild myopathy. Muscle and Nerve, 2017, 55, 919-922.	2.2	3
124	Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry). Orphanet Journal of Rare Diseases, 2020, 15, 187.	2.7	3
125	A case of <scp>ASAH1</scp>â€related pure SMA evolving into adultâ€onset Farber disease. Clinical Genetics, 2021, 100, 234-235.	2.0	3
126	Inclusion body myositis in patients with spinocerebellar ataxia types 3 and 6. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 876-878.	1.9	2

#	Article	IF	Citations
127	Type 1 FSHD with 6â€“10 Repeated Units: Factors Underlying Severity in Index Cases and Disease Penetrance in Their Relatives Attention. International Journal of Molecular Sciences, 2020, 21, 2221.	4.1	2
128	E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019. Journal of Neuromuscular Diseases, 2021, 8, 743-754.	2.6	2
129	Peut-on envisager une thÃ©rapie cellulaire autologue de la dystrophie musculaire facio-scapulo-humÃ©rale ?. Bulletin De L'Academie Nationale De Medecine, 2005, 189, 697-714.	0.0	2
130	The Splicing of the Mitochondrial Calcium Uniporter Genuine Activator MICU1 Is Driven by RBFOX2 Splicing Factor during Myogenic Differentiation. International Journal of Molecular Sciences, 2022, 23, 2517.	4.1	2
131	Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy. Orphanet Journal of Rare Diseases, 2022, 17, 96.	2.7	2
132	Current French Pompe Prevalence Study (French PoPS). Clinical Therapeutics, 2011, 33, S21.	2.5	1
133	The Potassium Channel Kir2.1 Activity is Required for Osteoblastogenesis. Biophysical Journal, 2012, 102, 538a.	0.5	1
134	G.P.245. Neuromuscular Disorders, 2014, 24, 890.	0.6	1
135	The impact of enzyme replacement therapy on the progression of Pompe disease. Neuromuscular Disorders, 2015, 25, S189.	0.6	1
136	Letter to the Editor on a paper by Hsiao C-T, Tsai P-C, Liao Y-C, Lee Y-C, Soong B-W. C9ORF72 repeat expansion is not a significant cause of late-onset cerebellar ataxia syndrome. J Neurol Sci 2014;347:322â€“324.. Journal of the Neurological Sciences, 2015, 351, 196-197.	0.6	1
137	Autophagy impairment in muscle biopsies from debranching enzyme deficiency (GSDIII) patients: pinpointing novel therapeutic perspectives. Neuromuscular Disorders, 2017, 27, S205-S206.	0.6	1
138	Scapular dyskinesis in myotonic dystrophy type 1: clinical characteristics and genetic investigations. Journal of Neurology, 2019, 266, 2987-2996.	3.6	1
139	A recurrent RYR1 mutation associated with early-onset hypotonia and benign disease course. Acta Neuropathologica Communications, 2021, 9, 155.	5.2	1
140	SMA â€“ OUTCOME MEASURES AND REGISTRIES. Neuromuscular Disorders, 2021, 31, S130-S131.	0.6	1
141	M.P.3.12 Characterization of COX16, a novel human gene required for cytochrome c oxidase assembly. Neuromuscular Disorders, 2007, 17, 830.	0.6	0
142	G.P.11.11 Phenotypes of Pompe disease siblings. Neuromuscular Disorders, 2008, 18, 803.	0.6	0
143	G.O.3 Contraction-dependent (FSHD1) and independent (FSHD2) epigenetic changes of D4Z4 unify FSHD. Neuromuscular Disorders, 2009, 19, 545.	0.6	0
144	Distrofia muscolare facio-scapolo-omerale. EMC - Neurologia, 2011, 11, 1-11.	0.0	0

#	Article	IF	Citations
145	O.19 Facioscapulohumeral muscular dystrophy: Muscle running out of control. Neuromuscular Disorders, 2011, 21, 749.	0.6	0
146	P3.52 Risk of dysrythmic cardiomyopathy may be considered in patients with adult onset Pompe diasease. Neuromuscular Disorders, 2011, 21, 698.	0.6	0
147	P.16.3 DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles. Neuromuscular Disorders, 2013, 23, 823.	0.6	0
148	G.O.7. Neuromuscular Disorders, 2014, 24, 851.	0.6	0
149	A.P.3. Neuromuscular Disorders, 2014, 24, 831.	0.6	0
150	Correlation between low FAT1 expression and early affected muscle in FSHD. Neuromuscular Disorders, 2015, 25, S312.	0.6	0
151	Large screening of patients diagnosed as limb girdle muscular dystrophy or congenital myopathy using Motorplex. Neuromuscular Disorders, 2015, 25, S297.	0.6	0
152	GNE myopathy: Characteristics of affected patients diagnosed in mainland France. Neuromuscular Disorders, 2016, 26, S169.	0.6	0
153	The EUROMAC registry for rare glycogen storage diseases: preliminary report. Neuromuscular Disorders, 2017, 27, S203-S204.	0.6	0
154	Expanding importance of HMERF titinopathy: new mutations and clinical aspects. Neuromuscular Disorders, 2017, 27, S237.	0.6	0
155	Morphological spectrum of RYR1 recessive myopathies: Clinical and genetic correlation.. Neuromuscular Disorders, 2017, 27, S239.	0.6	0
156	P.46Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, multi-center prospective study. Neuromuscular Disorders, 2019, 29, S54.	0.6	0
157	P.69NEO1 and NEO-EXT studies: exploratory efficacy of repeat avalglucosidase alfa dosing for up to 5 years in participants with late-onset Pompe disease (LOPD). Neuromuscular Disorders, 2019, 29, S60-S61.	0.6	0
158	P.120EUROMAC: A European registry for patients with McArdle disease and other very rare muscle glycogenoses. Neuromuscular Disorders, 2019, 29, S83.	0.6	0
159	P.306Multicentric MRI study in a cohort of FSHD2 patients: pattern definition and differences between FSHD1 and FSHD2. Neuromuscular Disorders, 2019, 29, S156.	0.6	0
160	P.398Usefulness of R-Pact scale for the follow-up of patients with late-onset Pompe disease: results from the French Pompe registry. Neuromuscular Disorders, 2019, 29, S198.	0.6	0
161	NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. Molecular Genetics and Metabolism, 2019, 126, S115-S116.	1.1	0
162	AUTOPHAGIC MYOPATHIES / MYOFIBRILLAR MYOPATHIES / DISTAL MYOPATHIES / POMPE DISEASE. Neuromuscular Disorders, 2020, 30, S49.	0.6	0

#	Article	IF	Citations
163	SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES. Neuromuscular Disorders, 2020, 30, S101.	0.6	0
164	FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2020, 30, S112.	0.6	0
165	FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2020, 30, S112.	0.6	0
166	CHANNELOPATHIES AND RELATED DISORDERS. Neuromuscular Disorders, 2021, 31, S116-S117.	0.6	0
167	CHANNELOPATHIES AND RELATED DISORDERS. Neuromuscular Disorders, 2021, 31, S118.	0.6	0
168	CHANNELOPATHIES AND RELATED DISORDERS. Neuromuscular Disorders, 2021, 31, S116.	0.6	0